Invega (paliperidone)
- Region
- 🇪🇺 EU
- Active substance
- paliperidone
- Company
- Janssen-Cilag International NV
- Status
- Authorised
- Therapeutic area
- Schizophrenia; Psychotic Disorders
- EU approval
- Sun 24 Jun 2007
- Application
- EMEA/H/C/000746
- ATC
- N05AX13
- Official record
- www.ema.europa.eu
Indication
Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older. Invega is indicated for the treatment of schizoaffective disorder in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Byannli (previously Paliperidone Janssen-Cilag International) Authorised ·
- 🇪🇺 Xeplion Authorised · Janssen-Cilag International
- 🇪🇺 Trevicta (previously Paliperidone Janssen) Authorised · Janssen-Cilag International NV
- 🇪🇺 Niapelf Authorised · Neuraxpharm Pharmaceuticals S.L.
Follow Invega
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.